For the patients who cannot wait.
DDIF convenes the leaders closing the gap.
DDIF 2027
Innovation that compounds.
Drug discovery without data architecture fails.
Clinical development without AI infrastructure stalls.
Models without the officer to deploy them are noise.
Every biotech has an AI narrative.
Few have the leader to execute it.
For the patients who cannot wait.
12–13 May 2027 · London · The Savoy London (invite only)
2026. Co-Chaired by Dr Harsukh Parmar and Dr Uwe Gottschalk.
Opening Keynote. Dr Laura Matz
Leading Partners
.
Dr Uwe Gottschalk
Operating Partner, Keensight Capital
Former CSO, Lonza Group
Architect of global biomanufacturing transformation
He leads because he spent three decades connecting discovery to manufacturing reality. From scaling monoclonal antibodies at Bayer to global bioprocessing strategy at Lonza, he knows that therapies fail not from bad science but from bad infrastructure.
Dr Harsukh Parmar
Former SVP, Global Head of Research & Early Development
Immunology & Neurology, EMD Serono / Merck KGaA
120+ molecules from discovery to development
He leads because he has taken more molecules from target to clinic than most companies attempt in a decade. Co-inventor of marketed therapies in oncology and immunology. 250+ publications. The rare scientist who has built what others benchmark.
.
Featuring
The gap doesn't close with algorithms.
The gap doesn't close with algorithms. It closes with the people who know how to deploy them.
DDIF brings together up to 150 leaders — those who've built the systems, deployed the platforms, connected the infrastructure. Members and invite only.
90% of drugs fail in clinical trials.
90% of drugs fail in clinical trials.
Discovery and development are converging. Not in science. In constraint.
AI-native drug discovery and traditional R&D face the same imperative: intelligence without deployment architecture fails.
Different modalities. Shared infrastructure. One operating future.
The gap between computational breakthrough and clinical delivery is where therapies stall, companies falter and patients wait. Davos called it the trust gap. JPM called it a leadership gap. We call it the officer gap.
Foundation models. Generative chemistry. Self-driving laboratories. Autonomous experimentation. Adaptive trials.
Real-world evidence.
Clinical data platforms. Decision architecture.
The leaders who govern all of it.
Partners
.png)
Not to just present.
To exchange.
What worked.
What failed.
What's next.
AIO Feature sponsored by Revvity Signals
Advisory Circle.
The Few Who Lead | GBX Advisory & Keynote Speakers
DDIF is Curated for
Chief Scientific Officers — R&D strategy, portfolio decisions, platform investments
Heads of Drug Discovery, Medicinal Chemistry and Computational Biology — target validation, Lab Automation - External Innovation, molecular design, candidate selection
CAIOs, Heads of AI, CTO and Chief Digital Officers — enterprise AI deployment, governance, decision architecture
Leaders in Data Science and Computational Infrastructure — foundation models, generative AI, predictive ADMET, data strategy
Clinical and Regulatory Executives — trial design, real-world evidence, regulatory strategy
DDIF 2026 Agenda
Pillars of Drug Discovery Innovation
1
Foundation
The data layer that decides everything. Your compound library is static. Your assay data is siloed. Foundation transforms decades of R&D investment into compounding intelligence. This is where ELN meets AI. Where LIMS becomes predictive. Where the officer has a platform — or does not.
2
Acceleration
Acceleration - From 10 years to 10 months.
AI-native companies are compressing discovery cycles by 70%. Self-driving laboratories do not sleep. Foundation models do not forget. Every month saved is a month gained for patients.
3
Autonomy
The lab that runs itself. Your best chemists spend 40% of their time on repetitive tasks. Self-driving laboratories do not sleep. Foundation models do not forget. This is not automation. This is decision architecture.
4
Translation
The graveyard of good molecules is full of bad data handoffs.
90% of drugs fail in clinical trials. Most failures trace back to discovery. Translation ensures design for developability. Chemistry for manufacturability.
5
Convergence
Convergence — Where living therapies meet living data. Cell and gene therapy does not follow the small molecule playbook. Every patient is a manufacturing run. The officer who governs discovery intelligence without manufacturing intelligence delivers a molecule that never reaches a patient.
The few committed to closing the gap.
 |  |  |  |  |
|---|
Join the Circle
Updates, Guest Access, Receive Invite, Gather → [Subscribe]